Cargando…

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

BACKGROUND: Ofatumumab (Arzerra(®), Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [double refractory (DR-CLL)]. Ofatumumab was licensed on the basis of an uncontrolled Phase II study, Hx-CD20-406, in which patients receiving ofatumumab survived f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatswell, Anthony J., Thompson, Gwilym J., Maroudas, Penny A., Sofrygin, Oleg, Delea, Thomas E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446681/ https://www.ncbi.nlm.nih.gov/pubmed/28559746 http://dx.doi.org/10.1186/s12962-017-0071-x

Ejemplares similares

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
por: AlDallal, Salma M
Publicado: (2017)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia
por: Hashimoto, Yu, et al.
Publicado: (2021)

Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
por: Cochran, Audra L, et al.
Publicado: (2023)

A meaningful exploration of ofatumumab in refractory NMOSD: a case report
por: Zhan, Yibo, et al.
Publicado: (2023)

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study
por: van Oers, Marinus, et al.
Publicado: (2019)

Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR
por: Huang, Tiangui, et al.
Publicado: (2013)

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
por: Donnellan, William, et al.
Publicado: (2017)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukaemia
por: Odeyinka, Oladipo, et al.
Publicado: (2022)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
por: Cao, Shugang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
por: Howard, Dena R., et al.
Publicado: (2021)

TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
por: Minervini, Crescenzio Francesco, et al.
Publicado: (2016)

Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia
por: Polychronidou, Eleftheria, et al.
Publicado: (2018)

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
por: Sydes, Matthew R, et al.
Publicado: (2012)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
por: Eyre, Toby A, et al.
Publicado: (2015)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
por: Delea, Thomas E., et al.
Publicado: (2019)

The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab
por: Zhang, Rui, et al.
Publicado: (2023)

The Arm Movement Detection (AMD) test: a fast robotic test of proprioceptive acuity in the arm
por: Mrotek, Leigh Ann, et al.
Publicado: (2017)

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Barrientos, Jacqueline C., et al.
Publicado: (2018)

Virtual reality environments for post-stroke arm rehabilitation
por: Subramanian, Sandeep, et al.
Publicado: (2007)

Econometric estimation of country-specific hospital costs
por: Adam, Taghreed, et al.
Publicado: (2003)

Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD)
por: Hiya, Satomi, et al.
Publicado: (2023)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
por: Xu, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_974h99dr38fq1knr7e6a0kc5da